Physician profile
Maria Hicks
NPI 1033376371
$23,515.58
in general payments reported to CMS, 2019-2025
43 companies · $7,979 in 2025
The $7,979 reported for 2025 was more than what 91% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,379 · 2020: $1,186 · 2021: $6,152 · 2022: $1,695 · 2023: $2,408 · 2024: $1,717 · 2025: $7,979.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,492 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,500 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,491.60 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,500.00 |
| Education | $112.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $5,866.12 | 2025 | Sofdra |
| Journey Medical Corporation | $3,344.95 | 2019-2023 | |
| Abbvie INC. | $1,726.19 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,555.88 | 2019-2025 | |
| Almirall LLC | $1,079.31 | 2019-2025 | Seysara |
| Pfizer INC. | $963.29 | 2019-2025 | |
| Ucb, INC. | $795.15 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $785.81 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Leo Pharma INC. | $772.38 | 2019-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $720.04 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Janssen Biotech, INC. | $713.45 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Regeneron Healthcare Solutions, INC. | $703.34 | 2019-2025 | Libtayo, Dupixent |
| Galderma Laboratories, L.P. | $664.34 | 2019-2025 | Nemluvio, Twyneo, Oracea |
| Genzyme Corporation | $654.53 | 2019-2025 | |
| Biofrontera INC. | $558.10 | 2019-2023 | Xepi, Bf-Rhodoled, Ameluz |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Hicks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.